Advertisement

Investigational New Drugs

, Volume 29, Issue 5, pp 996–1003 | Cite as

A dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies

  • Benoit You
  • Anthony Brade
  • Joao M. Magalhaes
  • Lillian L. Siu
  • Amit Oza
  • Sonya Lovell
  • Lisa Wang
  • David W. Hedley
  • Leonardo V. Nicacio
  • Eric X. Chen
PHASE I STUDIES

Summary

Purpose: Nimotuzumab is a humanized monoclonal antibody which inhibits the ligand-dependent activation of epidermal growth factor receptor (EGFR). We conducted a phase I trial to assess the pharmacodynamic (PD) effects of escalating doses of nimotuzumab administered alone in patients with advanced solid cancers patients. Experimental design: Patients were treated with escalating doses of weekly intravenous nimotuzumab at doses ranging between 100 and 800 mg. Tumor and skin biopsies were done before start of treatment and repeated 3 weeks after to assess immunohistochemical expression of EGFR and its downstream components. Results: Seventeen patients were enrolled, including 1 patient never treated. Although 1 dose-limiting-toxicity (DLT) was observed at 100 mg (grade 3 fatigue), nimotuzumab dose was escalated to 800 mg with no other DLT. No grade 4 toxicity was observed. Only 3 patients developed a grade 1 acneiform rash (18.7%). One patient achieved a partial response (6.2%) and 8 patients had stable disease (50.0%). The median TTP was 2.4 months. No significant changes in EGFR, AKT, ERK and Ki67 immuno-stainings were observed between pre- and on-treatment tumor or skin biopsies. Conclusion: Nimotuzumab could be safety administered up to 800 mg with manageable toxicity. No relationships were found between pharmacodynamic effects on EGFR downstream signaling pathways and drug efficacy or toxicity.

Keywords

Nimotuzumab Antibodies Monoclonal Clinical Trial, Phase I Epidermal growth factor receptor 

Notes

Acknowledgements

Benoit You received academic grants from Académie Française (Bourse J. Walter-Zellidja) and from Centre Léon Bérard (Bourse M. Clavel).

References

  1. 1.
    Mendelsohn J, Baselga J (2003) Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21:2787–2799PubMedCrossRefGoogle Scholar
  2. 2.
    Rivera F, Vega-Villegas ME, Lopez-Brea MF, Marquez R (2008) Current situation of Panitumumab, Matuzumab, Nimotuzumab and Zalutumumab. Acta Oncol 47:9–19PubMedCrossRefGoogle Scholar
  3. 3.
    Crombet T, Osorio M, Cruz T, Roca C, del Castillo R, Mon R, Iznaga-Escobar N, Figueredo R, Koropatnick J, Renginfo E, Fernandez E, Alvarez D, Torres O, Ramos M, Leonard I, Perez R, Lage A (2004) Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 22:1646–1654PubMedCrossRefGoogle Scholar
  4. 4.
    Crombet T, Torres L, Neninger E, Catala M, Solano ME, Perera A, Torres O, Iznaga N, Torres F, Perez R, Lage A (2003) Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer. J Immunother 26:139–148PubMedCrossRefGoogle Scholar
  5. 5.
    Talavera A, Friemann R, Gomez-Puerta S, Martinez-Fleites C, Garrido G, Rabasa A, Lopez-Requena A, Pupo A, Johansen RF, Sanchez O, Krengel U, Moreno E (2009) Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation. Cancer Res 69:5851–5859PubMedCrossRefGoogle Scholar
  6. 6.
    Crombet-Ramos T, Rak J, Perez R, Viloria-Petit A (2002) Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: A humanized anti-EGFR antibody. Int J Cancer 101:567–575PubMedCrossRefGoogle Scholar
  7. 7.
    Nair P, Sierra P, Shivu J, Basavaraj C, Melarkode R (2008) Relevance of biomarkers in a phase IIB head and neck trial using nimotuzumab. ASCO 2008 Molecular Markers Proceedings (Abs. 57)Google Scholar
  8. 8.
    Rojo F, Gracias E, Villena N, Cruz T,Corradino I, Cedeño M, Campas C, Sessa C, Crombet T, Albanell J (2008) Pharmacodynamic study of nimotuzumab, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody (MAb), in patients with unresectable squamous cell carcinoma of the head and neck (SCCHN): A SENDO Foundation study. J Clin Oncol 26(Suppl. 20):2008 ASCO Annual Meeting Proceedings (Abs. 6070)Google Scholar
  9. 9.
    Huang XD, Yi JL, Gao L, Xu GZ, Jin J, Yang WZ, Lu TX, Wu SX, Wu RR, Hu WH, Xie WC, Han F, Gao YH, Gao JM, Pan JJ, Chen CB, Lang JY, Li T, Dong Y, Fu YB, Fan L, Li BS, Li J, Wang XH, Chen BX, Gao XS, Zhang P, Wu XW, Hu BQ (2007) Multi-center phase II clinical trial of humanized anti-epidermal factor receptor monoclonal antibody h-R3 combined with radiotherapy for locoregionally advanced nasopharyngeal carcinoma. Zhonghua Zhong Liu Za Zhi 29:197–201PubMedGoogle Scholar
  10. 10.
    Wu RR, Wu SX, Zhao C, Xie FY, Gao JM, Hu WH, Gao YH, Li FY, Cui TT, Lu TX (2007) Phase II clinical trial of h-R3 combined radiotherapy for locoregionally advanced nasopharyngeal carcinoma. Ai Zheng 26:874–879PubMedGoogle Scholar
  11. 11.
    Bode U, Buchen S, Warmuth-Metz M, Pietsch T, Bach F, Fleischhack G (2007) Final report of a phase II trial of nimotuzumab in the treatment of refractory and relapsed high-grade gliomas in children and adolescents. J Clin Oncol 25(Suppl. 18):2007 ASCO Annual Meeting Proceedings (Abs. 2006)Google Scholar
  12. 12.
    Ramos TC, Figueredo J, Catala M, Gonzalez S, Selva JC, Cruz TM, Toledo C, Silva S, Pestano Y, Ramos M, Leonard I, Torres O, Marinello P, Perez R, Lage A (2006) Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial. Cancer Biol Ther 5:375–379PubMedCrossRefGoogle Scholar
  13. 13.
    Bebb D, Brade AM, Smith C, Rorke S, Sherman I (2008) Preliminary results of an escalating dose phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab in combination with external radiotherapy in patients diagnosed with stage IIb, III or IV non-small cell lung cancer unsuitable for radical therapy. J Clin Oncol 26(Suppl. 20):2008 ASCO Annual Meeting Proceedings (Abs. 3037)Google Scholar
  14. 14.
    Casaco A, Lopez G, Garcia I, Rodriguez JA, Fernandez R, Figueredo J, Torres L, Perera A, Batista J, Leyva R, Pena Y, Amador Z, Gonzalez A, Estupinan B, Coca M, Hernandez A, Puig M, Iglesias M, Ramos M, Rodriquez L, Suarez N (2008) Phase I single-dose study of intracavitary-administered Nimotuzumab labeled with 188 Re in adult recurrent high-grade glioma. Cancer Biol Ther 7:333–339PubMedCrossRefGoogle Scholar
  15. 15.
    Torres LA, Perera A, Batista JF, Hernandez A, Crombet T, Ramos M, Neninger E, Perez M, Sanchez EL, Romero S, Aguilar V, Coca MA, Iznaga-Escobar N (2005) Phase I/II clinical trial of the humanized anti-EGF-r monoclonal antibody h-R3 labelled with 99mTc in patients with tumour of epithelial origin. Nucl Med Commun 26:1049–1057PubMedCrossRefGoogle Scholar
  16. 16.
    Vallis KA, Reilly RM, Chen P, Oza A, Hendler A, Cameron R, Hershkop M, Iznaga-Escobar N, Ramos-Suzarte M, Keane P (2002) A phase I study of 99mTc-hR3 (DiaCIM), a humanized immunoconjugate directed towards the epidermal growth factor receptor. Nucl Med Commun 23:1155–1164PubMedCrossRefGoogle Scholar
  17. 17.
    Shah A, Chen E, Jonker D, Zibdawi I, Mackenzie M, Walde J, Siddqui J, Knight G, Rother M, Bebb G (2009) A phase II clinical trial of nimotuzumab, an EGFR monoclonal antibody, in metastatic colorectal cancer. 2009 Gastrointestinal Cancers Symposium Proceedings (Abs. 358)Google Scholar
  18. 18.
    Strumberg D, Scheulen ME, Hilger RA, Krauss J, Marschner N, Lordick F, Bach F, Reuter D, Edler L, Mross K (2006) Safety, efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, as monotherapy in patients with locally advanced or metastatic pancreatic cancer (PC). J Clin Oncol 24(Suppl.18):2006 ASCO Annual Meeting Proceedings (Abs. 12504)Google Scholar
  19. 19.
    Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216PubMedCrossRefGoogle Scholar
  20. 20.
    Pham NA, Morrison A, Schwock J, Aviel-Ronen S, Iakovlev V, Tsao MS, Ho J, Hedley DW (2007) Quantitative image analysis of immunohistochemical stains using a CMYK color model. Diagn Pathol 2:8PubMedCrossRefGoogle Scholar
  21. 21.
    Alekshun T, Garrett C (2005) Targeted therapies in the treatment of colorectal cancers. Cancer Control 12:105–110PubMedGoogle Scholar
  22. 22.
    Capdevila J, Elez E, Macarulla T, Ramos FJ, Ruiz-Echarri M, Tabernero J (2009) Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment. Cancer Treat Rev 35:354–363PubMedCrossRefGoogle Scholar
  23. 23.
    Garrido G, Rabasa A, Gracia E, Tikhirov I, Crombet-Ramos T, Viloria-Petit A, Kerbel R, Yang E, Perez R (2009) Binding properties of the anti-EGFR monoclonal antibody, nimotuzumab, limit its interaction with the EGFR in renal and epidermal cells. 2009 AACR Annual Meeting Proceedings (Abs. 2763)Google Scholar
  24. 24.
    Newman M, Gerami P, Guitart J, Lertsburapa T, West D, Rosen S, Cianfrocca M, Lacouture M (2009) Histological differentiation of skin toxicity between cetuximab, erlotinib and panitumumab (single ErbB1) and lapatinib (dual ErbB1/2) epidermal growth factor receptor inhibitors. J Clin Oncol 27(Suppl.):2009 ASCO Annual Meeting Proceedings (Abs. e20617)Google Scholar
  25. 25.
    Tikhomirov I, Hidalgo G, Yang E, Sherman I, Rodriguez R (2009) Bivalent binding properties of epidermal growth factor receptor targeted monoclonal antibodies: facots contributing to differences in observed clinical profiles. 2009 AACR Annual Meeting Proceedings (Abs. A36)Google Scholar
  26. 26.
    Debucquoy A, Haustermans K, Daemen A, Aydin S, Libbrecht L, Gevaert O, De Moor B, Tejpar S, McBride WH, Penninckx F, Scalliet P, Stroh C, Vlassak S, Sempoux C, Machiels JP (2009) Molecular response to cetuximab and efficacy of preoperative cetuximab-based chemoradiation in rectal cancer. J Clin Oncol 27:2751–2757PubMedCrossRefGoogle Scholar
  27. 27.
    Milas L, Mason K, Hunter N, Petersen S, Yamakawa M, Ang K, Mendelsohn J, Fan Z (2000) In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 6:701–708PubMedGoogle Scholar
  28. 28.
    Maréchal R, Nagy N, Verrellen A, Larsimont D, Hendlisz A, Demols A, Demetter P, Van Laethem J (2008) NK cells infiltrate in primary tumor influences response to cetuximab (CTX) in first-line therapy of metastatic colorectal cancer (mCRC). J Clin Oncol 26(Suppl. 20):2008 ASCO Annual Meeting Proceedings (Abs 22008)Google Scholar
  29. 29.
    Fracasso PM, Burris H 3rd, Arquette MA, Govindan R, Gao F, Wright LP, Goodner SA, Greco FA, Jones SF, Willcut N, Chodkiewicz C, Pathak A, Springett GM, Simon GR, Sullivan DM, Marcelpoil R, Mayfield SD, Mauro D, Garrett CR (2007) A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing. Clin Cancer Res 13:986–993PubMedCrossRefGoogle Scholar
  30. 30.
    Tan AR, Moore DF, Hidalgo M, Doroshow JH, Poplin EA, Goodin S, Mauro D, Rubin EH (2006) Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors. Clin Cancer Res 12:6517–6522PubMedCrossRefGoogle Scholar
  31. 31.
    Mandell JW (2003) Phosphorylation state-specific antibodies: applications in investigative and diagnostic pathology. Am J Pathol 163:1687–1698PubMedCrossRefGoogle Scholar
  32. 32.
    Paavilainen L, Edvinsson A, Asplund A, Hober S, Kampf C, Ponten F, Wester K (2010) The impact of tissue fixatives on morphology and antibody-based protein profiling in tissues and cells. J Histochem Cytochem 58:237–246PubMedCrossRefGoogle Scholar
  33. 33.
    Vale C, Tierney J, Meade A, Fisher D, Kaplan R, Adams R, Maughan T, Parmar M (2009) Impact of K-ras status on the effects of EGFR-targeted monoclonal antibody (MAb) therapy in advanced colorectal cancer (ACRC): A systematic review and meta-analysis of randomized controlled trials (RCTs). J Clin Oncol 27(Suppl.):2009 ASCO Annual Meeting Proceedings (Abs 4122)Google Scholar
  34. 34.
    Van Cutsem E, Rougier P, Köhne C, Stroh C, Schlichting M, Bokemeyer C (2009) A meta-analysis of the CRYSTAL and OPUS studies combining cetuximab with chemotherapy (CT) as 1st-line treatment for patients (pts) with metastatic colorectal cancer (mCRC): Results according to KRAS and BRAF mutation status. Eur J Cancer Supplements 7(2):2009 ECCO15-ESMO34 Multidisciplinary Congress Proceedings (Abs P-6077)Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Benoit You
    • 1
  • Anthony Brade
    • 1
  • Joao M. Magalhaes
    • 1
    • 2
  • Lillian L. Siu
    • 1
  • Amit Oza
    • 1
  • Sonya Lovell
    • 1
  • Lisa Wang
    • 1
  • David W. Hedley
    • 1
    • 2
  • Leonardo V. Nicacio
    • 3
  • Eric X. Chen
    • 1
    • 4
  1. 1.Department of Medical Oncology and Hematology, Princess Margaret HospitalUniversity Health NetworkTorontoCanada
  2. 2.Ontario Cancer Institute, and Department of Laboratory Medicine and PathologyUniversity of TorontoTorontoCanada
  3. 3.YM BioSciences Inc.MississaugaCanada
  4. 4.Department of Medical Oncology and HematologyPrincess Margaret HospitalTorontoCanada

Personalised recommendations